BioSpace News Archive

Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Securities and Exchange Commission, the first amendment to its registration statement on Form S-4, filed on March 15, 2022.

Applications of augmented reality (AR) in the healthcare sector are gaining momentum. New advancements in AR technology is aimed at providing assistance to the healthcare professionals including nurses, surgeons, lab assistants, and physicians.

The healthcare industry is set to be revolutionized with the implementation of chatbots. These chatbots are powered by advanced technologies such as artificial intelligence (AI), natural language processing (NLP), and machine learning.

Freeline Therapeutics Holdings plc announced that on March 31, 2022, the Company granted its newly hired Chief Scientific Officer, Henning Stennicke, PhD, and two other newly hired employees non-statutory options to purchase an aggregate of 240,000 and 159,000 of the Company’s ordinary shares, respectively.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference.

Cara Therapeutics, Inc. KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.

Venus Concept Inc. announced today that first quarter of fiscal year 2022 financial results will be released after the market closes on Thursday, May 12, 2022.

Viridian Therapeutics, Inc. announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. for up to $75 million.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on Monday, April 11, at 11:00 a.m. ET.

Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem Cell Institute, on April 11, 2022, at 3:00 PM ET.